Format

Send to

Choose Destination
Br Med Bull. 2015;116:19-27. doi: 10.1093/bmb/ldv045. Epub 2015 Nov 17.

Human embryonic and induced pluripotent stem cells in clinical trials.

Author information

1
Stem Cell Laboratories, Guy's Assisted Conception Unit, Division of Women's Health, Faculty of Life Sciences and Medicine, King's College London, London, UK dusko.ilic@kcl.ac.uk.
2
Stem Cell Laboratories, Guy's Assisted Conception Unit, Division of Women's Health, Faculty of Life Sciences and Medicine, King's College London, London, UK.
3
ST8Biologics, London, UK.

Abstract

BACKGROUND:

Human embryonic and induced pluripotent stem cells (hESC and hiPSC) have tremendous potential for clinical implementation. In spite of all hurdles and controversy, clinical trials in treatment of spinal cord injury, macular degeneration of retina, type 1 diabetes and heart failure are already ongoing.

SOURCES OF DATA:

ClinicalTrials.gov database, International Clinical Trials Registry Platform, PubMed and press releases and websites of companies and institutions working on hESC- and iPSC-based cellular therapy.

AREAS OF AGREEMENT:

The initial results from multiple clinical trials demonstrate that hESC-based therapies are safe and promising.

AREAS OF CONTROVERSY:

Are iPSC cells safe in the clinical application? Is there a room for both hESC and iPSC in the future clinical applications?

GROWING POINTS:

Increasing number of new clinical trials.

AREAS TIMELY FOR DEVELOPING RESEARCH:

Development of hESC- and/or iPSC-based cellular therapy for other diseases.

KEYWORDS:

diabetes; heart repair; human embryonic stem cells (hESC); human induced pluripotent stem cells (hiPSC); macular degeneration; spinal cord injury

PMID:
26582538
DOI:
10.1093/bmb/ldv045
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center